Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 146

Cited In for PubMed (Select 20300106)

1.
2.

Maternal undernutrition and cardiometabolic disease: a Latin American perspective.

Lopez-Jaramillo P, Gomez-Arbelaez D, Sotomayor-Rubio A, Mantilla-Garcia D, Lopez-Lopez J.

BMC Med. 2015 Mar 2;13:41. doi: 10.1186/s12916-015-0293-8.

3.

Modelling the effect of SPION size in a stent assisted magnetic drug targeting system with interparticle interactions.

Mardinoglu A, Cregg PJ.

ScientificWorldJournal. 2015;2015:618658. doi: 10.1155/2015/618658. Epub 2015 Mar 1.

4.

A Novel Pyruvate Kinase M2 Activator Compound that Suppresses Lung Cancer Cell Viability under Hypoxia.

Kim DJ, Park YS, Kim ND, Min SH, You YM, Jung Y, Koo H, Noh H, Kim JA, Park KC, Yeom YI.

Mol Cells. 2015 Apr 30;38(4):373-9. doi: 10.14348/molcells.2015.2314. Epub 2015 Mar 26.

5.

Metabolic signature identifies novel targets for drug resistance in multiple myeloma.

Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, Asara JM, Roccaro AM, Kimmelman AC, Ghobrial IM.

Cancer Res. 2015 May 15;75(10):2071-82. doi: 10.1158/0008-5472.CAN-14-3400. Epub 2015 Mar 13.

PMID:
25769724
6.

Regulation of mammalian nucleotide metabolism and biosynthesis.

Lane AN, Fan TW.

Nucleic Acids Res. 2015 Feb 27;43(4):2466-85. doi: 10.1093/nar/gkv047. Epub 2015 Jan 27.

7.

Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question.

Alfarouk KO, Verduzco D, Rauch C, Muddathir AK, Adil HH, Elhassan GO, Ibrahim ME, David Polo Orozco J, Cardone RA, Reshkin SJ, Harguindey S.

Oncoscience. 2014 Dec 18;1(12):777-802. eCollection 2014.

8.

Targeting T cell metabolism for therapy.

O'Sullivan D, Pearce EL.

Trends Immunol. 2015 Feb;36(2):71-80. doi: 10.1016/j.it.2014.12.004. Epub 2015 Jan 15. Review.

PMID:
25601541
9.
10.

Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.

Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, Jordan CT, Serkova NJ, Graham DK, DeGregori J.

Clin Cancer Res. 2015 Mar 15;21(6):1360-72. doi: 10.1158/1078-0432.CCR-14-2146. Epub 2014 Dec 29.

PMID:
25547679
11.

Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment.

Ruggieri V, Agriesti F, Scrima R, Laurenzana I, Perrone D, Tataranni T, Mazzoccoli C, Lo Muzio L, Capitanio N, Piccoli C.

Oncotarget. 2015 Jan 20;6(2):1217-30.

12.

The clinicopathologic importance of serum lactic dehydrogenase in patients with gastric cancer.

Zhao Z, Han F, Yang S, Hua L, Wu J, Zhan W.

Dis Markers. 2014;2014:140913. doi: 10.1155/2014/140913. Epub 2014 Nov 4.

13.

A long noncoding RNA connects c-Myc to tumor metabolism.

Hung CL, Wang LY, Yu YL, Chen HW, Srivastava S, Petrovics G, Kung HJ.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18697-702. doi: 10.1073/pnas.1415669112. Epub 2014 Dec 15.

14.

Apoptotic efficacy of etomoxir in human acute myeloid leukemia cells. Cooperation with arsenic trioxide and glycolytic inhibitors, and regulation by oxidative stress and protein kinase activities.

Estañ MC, Calviño E, Calvo S, Guillén-Guío B, Boyano-Adánez Mdel C, de Blas E, Rial E, Aller P.

PLoS One. 2014 Dec 15;9(12):e115250. doi: 10.1371/journal.pone.0115250. eCollection 2014.

15.

Dengue virus induces and requires glycolysis for optimal replication.

Fontaine KA, Sanchez EL, Camarda R, Lagunoff M.

J Virol. 2015 Feb;89(4):2358-66. doi: 10.1128/JVI.02309-14. Epub 2014 Dec 10.

PMID:
25505078
16.

Regulation of substrate utilization by the mitochondrial pyruvate carrier.

Vacanti NM, Divakaruni AS, Green CR, Parker SJ, Henry RR, Ciaraldi TP, Murphy AN, Metallo CM.

Mol Cell. 2014 Nov 6;56(3):425-35. doi: 10.1016/j.molcel.2014.09.024. Epub 2014 Oct 30.

PMID:
25458843
17.

A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth.

Schell JC, Olson KA, Jiang L, Hawkins AJ, Van Vranken JG, Xie J, Egnatchik RA, Earl EG, DeBerardinis RJ, Rutter J.

Mol Cell. 2014 Nov 6;56(3):400-13. doi: 10.1016/j.molcel.2014.09.026. Epub 2014 Oct 21.

PMID:
25458841
18.

Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.

Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, He T, Shi C, Bedel O, McLean LR, Le-Strat F, Zhang Y, Marquette JP, Gao Q, Zhang B, Rak A, Hoffmann D, Rooney E, Vassort A, Englaro W, Li Y, Patel V, Adrian F, Gross S, Wiederschain D, Cheng H, Licht S.

J Biol Chem. 2015 Jan 9;290(2):762-74. doi: 10.1074/jbc.M114.608497. Epub 2014 Nov 12.

PMID:
25391653
19.

Different effects of LDH-A inhibition by oxamate in non-small cell lung cancer cells.

Yang Y, Su D, Zhao L, Zhang D, Xu J, Wan J, Fan S, Chen M.

Oncotarget. 2014 Dec 15;5(23):11886-96.

20.

In vitro assessment of antitumor activities of the PI3K/mTOR inhibitor GSK2126458.

Albawardi A, Al Ayyan M, Al Bashir M, Souid AK, Almarzooqi S.

Cancer Cell Int. 2014 Sep 24;14(1):90. doi: 10.1186/s12935-014-0090-z. eCollection 2014.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk